Dapagliflozin with insulin for patients with Type 1 Diabetes

11th October 2019 by Louise Hudman

Dapagliflozin with insulin for patients with Type 1 Diabetes

This is a new guideline from NICE on using dapagliflozin in patients with Type 1 diabetes. It was published in Aug 19.

Key learning points for me:

  • There is a rise in the risk of ketoacidosis.
  • It needs stopping if there is a sustained fall in GFR to < 45.

The main concern with using dapagliflozin alongside insulin in patients with Type 1 diabetes (T1DM) is that there is an almost two-fold rise in the risk of diabetic ketoacidosis. However the absolute risk is not that high. Because of this, quite rigid restrictions have been placed on who is eligible.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

Related content

"I have been working with NASGP as the main source of income since graduating. I can't recommend them more highly for newly-graduated GPs. They helped me with setting my terms and conditions and they even arranged a tutorial session about EMIS, as the system was new to me.

LocumDeck is a great help when it comes to organising sessions, pension forms and invoices for tax purposes.

NASGP was particularly supportive during the Covid-19 period. It recognised the effect it had on locum work, temporarily waived the already small fee on sessions and were keen on getting the members together in regular video meetings.

I'm a satisfied member of NASGP. "

Dr Nazar Ahmed

Dr Nazar Ahmed

See the full list of features within our NASGP membership plans

Membership